Receptors nomenclature

In general the receptor nomenclature used is consistent with the recommendations of the various International Union of Pharmacology (lUPHAR) Committee on receptor nomenclature (19,20). In some cases the human receptor has been cloned. By convention, pharmacologicaUy defined receptors are shown ia capital letters cloaed receptors ia lower case letters. 

Murphy PM. International Union of Pharmacology. Update on chemokine receptor nomenclature. Pharmacol Rev 2002 54 227-229. 

Hartig, P. R., Hoyer, D., Humphrey, P. P. A. and Martin, G. Alignment of receptor nomenclature with the human genome classification of 5-HT1B and 5-HT1D receptor subtypes. Trends Pharmacol. Sci. 17 103-105,1996. 

Neubig, R.R., Spedding, M., Kenakin, T., and Christopoulos, A., International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology, Pharmacol. Rev., 55, 597, 2003. 

Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell 97 161-163. 

The P2 receptor nomenclature was prompted by evidence that extracellular ATP works through two different transduction mechanisms, namely intrinsic ion channels and G-protein coupled receptors (Benham and Tsien, 1987 Dubyak, 1991). In 1994 it was formally suggested that P2 receptors should be divided into two groups termed P2X and P2Y according to whether they are ligand-gated ion channels (Fig. 1) or are coupled to G-proteins - metabotropic receptors belonging to the heptahelical superfamily (Abbracchio and Burnstock, 1994 Barnard et al., 1994 Fredholm etal., 1994). 

Fig. 29. Distribution of D5/iB receptors in representative sections of the rat brain. Although, as specified in the text, the receptor nomenclature is D1B in rodents and D5 in primates, the map has been labeled as D5 to avoid any confusion with Fig. 22. See the legend to Fig. 22 for further details.

The IUPHAR Committee on Receptor Nomenclature and Drug Classification. The IUPHAR Compendium of Receptor Characterization and Classification, 2nd ed IUPHAR Media 2000. 

Opioid Nomenclature Proposal, Revised lUPHAR Opioid Receptor Nomenclature Subcommittee Proposal, International Nar-- codes Research (Conference, Seattle, WA, 2000. 

Jenkinson DH, Barnard EA, Hoyer D, ef a/. 1995. International union of pharmacology committee on receptor nomenclature and drug classification. IX. 

The nuclear receptor superfamily can be generally divided into four major subfamilies based on their DNA-binding properties and dimerization preferences. However, this classification is rather broad and does not take into account of any evolutionary relationship between nuclear receptors. Therefore, a new phylogeny-based nomenclature approved by the Nuclear Receptor Nomenclature... 

Tetraamines were shown to be competitive antagonists of muscarinic receptors. Melchiorre et al. (1987) presented in J. Med. Chem. the most potent and cardioselective compound of this class, methoctramine (Fig. 2), displaying a selectivity ratio (atria vs. ileum or bladder) of ca. 270. TIPS (1989) showed a picture of muscarinic receptor nomenclature recommended by the Fourth International Symposium on Subtypes of Muscarinic Receptors (Wiesbaden, 1989) where three pharmacologically defined muscarinic subtypes (M1-M3) and five cloned muscarinic subtypes are placed side by side. Among the selective antagonists showed in this classification, p-fluorohexa-hydrosila-difenidol appears (Lambrecht et al., 1989) as a new Mj-selective compound (Fig. 2). In the aforementioned Symposium, Eberlein et al. (1989) presented AF-DX 384 (Fig. 2), a successor of AF-DX 116. 

---